These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 31105858)
1. Impact of gene polymorphism on the initiation and maintenance phases of warfarin therapy in Chinese patients undergoing heart valve replacement. Liu J; Guan H; Zhou L; Cui Y; Cao W; Wang L Am J Transl Res; 2019; 11(4):2507-2515. PubMed ID: 31105858 [TBL] [Abstract][Full Text] [Related]
2. Effect of gene polymorphims on the warfarin treatment at initial stage. Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206 [TBL] [Abstract][Full Text] [Related]
3. The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin. Jiang HH; Liu J; Wang YC; Ye HM; Li X; Zhou YX; Zhang W; Wang LS Clin Appl Thromb Hemost; 2018 May; 24(4):640-646. PubMed ID: 28401802 [TBL] [Abstract][Full Text] [Related]
4. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study. Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620 [TBL] [Abstract][Full Text] [Related]
5. Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation. Li J; Yang W; Xie Z; Yu K; Chen Y; Cui K BMC Cardiovasc Disord; 2018 May; 18(1):96. PubMed ID: 29776386 [TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis. Zhang J; Chen Z; Chen C Meta Gene; 2016 Sep; 9():197-209. PubMed ID: 27617219 [TBL] [Abstract][Full Text] [Related]
7. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy]. Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278 [TBL] [Abstract][Full Text] [Related]
8. [Development of the high resolution melting method for genotyping CYP2C9*3 (1075A/C, rs1057910) and VKORC1 (-1639A/G, rs9923231)]. Cui GL; Ding H; Xu YJ; Chen C; Wang DW Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Jun; 40(6):477-81. PubMed ID: 22943641 [TBL] [Abstract][Full Text] [Related]
9. Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage. Wang LS; Shang JJ; Shi SY; Zhang YQ; Lin J; Guo ZH; Wang YC; Tang J; Liu J; Liu YZ; Li Z; Tan ZR; Zhou HH; Jiang HH; Xie HT Eur J Clin Pharmacol; 2013 May; 69(5):1113-20. PubMed ID: 23208322 [TBL] [Abstract][Full Text] [Related]
10. Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. Luxembourg B; Schneider K; Sittinger K; Toennes SW; Seifried E; Lindhoff-Last E; Oldenburg J; Geisen C Thromb Haemost; 2011 Jan; 105(1):169-80. PubMed ID: 21057703 [TBL] [Abstract][Full Text] [Related]
11. Warfarin dosage response related pharmacogenetics in Chinese population. Li S; Zou Y; Wang X; Huang X; Sun Y; Wang Y; Dong L; Jiang H PLoS One; 2015; 10(1):e0116463. PubMed ID: 25594941 [TBL] [Abstract][Full Text] [Related]
12. Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy. Al-Eitan LN; Almasri AY; Khasawneh RH Saudi Pharm J; 2019 May; 27(4):484-490. PubMed ID: 31061616 [TBL] [Abstract][Full Text] [Related]
13. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746 [TBL] [Abstract][Full Text] [Related]
14. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage]. Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578 [TBL] [Abstract][Full Text] [Related]
15. Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients. Jiang NX; Ge JW; Xian YQ; Huang SY; Li YS Biomed Rep; 2016 Apr; 4(4):453-458. PubMed ID: 27073631 [TBL] [Abstract][Full Text] [Related]
16. CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation. Nahar R; Saxena R; Deb R; Parakh R; Shad S; Sethi PK; Takkar P; Verma IC Pharmacol Rep; 2014 Apr; 66(2):243-9. PubMed ID: 24911077 [TBL] [Abstract][Full Text] [Related]
17. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves. An SH; Lee KE; Chang BC; Gwak HS J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049 [TBL] [Abstract][Full Text] [Related]
18. Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement. Liu R; Cao J; Zhang Q; Shi XM; Pan XD; Dong R Medicine (Baltimore); 2017 Jan; 96(2):e5658. PubMed ID: 28079798 [TBL] [Abstract][Full Text] [Related]
19. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342 [TBL] [Abstract][Full Text] [Related]